CN1413590A - Cancer prevention oral medicine - Google Patents
Cancer prevention oral medicine Download PDFInfo
- Publication number
- CN1413590A CN1413590A CN 01127482 CN01127482A CN1413590A CN 1413590 A CN1413590 A CN 1413590A CN 01127482 CN01127482 CN 01127482 CN 01127482 A CN01127482 A CN 01127482A CN 1413590 A CN1413590 A CN 1413590A
- Authority
- CN
- China
- Prior art keywords
- cancer prevention
- oral medicine
- prevention oral
- food
- aspirin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral-applied anticancer medicine contains aspirin (10-30 wt%), seaweed polyose (15-45), VC (25-60), food sterol (15-45), etc.
Description
Technical field
The present invention relates to a kind of medicine of anti-curing cancers.
Background technology
At present, cancer is that malignant tumor is a kind of pertinacious disease of harm humans health and life, and it is sizable to the misery that the patient caused, and its cure rate also is lower.The mankind mostly take modes such as operation, radiotherapy, chemotherapy up to now constantly exploring these treatment of conditions means for a long time, and its effect is not only all not very good, and all has many drawbacks separately.How fundamentally prophylaxis of cancer, effectively stop the generation of cancer, avoid its harm humans health and life, be that a great problem to be solved is arranged at present.
Summary of the invention
Purpose of the present invention provides a kind of cancer prevention oral medicine, and the problem of its harm humans health and life is avoided in the generation that it can solve prophylaxis of cancer fundamentally, stop cancer.
Cancer prevention oral medicine of the present invention, it comprises (in the weight portion) that following component is made:
Aspirin 10-30
Sargassum polysaccharides 15-45
Vitamin C 25-60
Food sterin 15-45
Hydrogen meter androsterone 20-60
Lycopene 25-50
The formula optimization weight portion ratio range of preparation medicine of the present invention:
Aspirin 10-25
Sargassum polysaccharides 15-40
Vitamin C 25-50
Food sterin 15-40
Hydrogen meter androsterone 20-50
Lycopene 25-40
The formula optimization weight portion ratio range of preparation medicine of the present invention:
Aspirin 15-20
Sargassum polysaccharides 20-30
Vitamin C 30-40
Food sterin 20-30
Hydrogen meter androsterone 30-40
Lycopene 30-35
Optimum weight part proportioning of the present invention:
Aspirin 20
Sargassum polysaccharides 20
Vitamin C 30
Food sterin 30
Hydrogen meter androsterone 30
Lycopene 30
The invention has the beneficial effects as follows: it is from the theory of " seeing malignant tumor by life automatic control message sense visual angle ", the clear and definite cause of disease of malignant tumor, and it is the defective of privileged sites of microstructure of the gene of living and the appearance of damage.Its main points of view is, cell is as the basic composition unit of life, it has life automatic control information system, be the microcosmic existence form of gene, this system is controlling all movable and whole life processes of cell, and this system is made up of each different section, difference continuity mutually again mutually between each section, the part of each section control life process, as propagation section, growth section, ripe section, functional section etc., each section is a process by quantitative change to qualitative change from start to finish.Therefore, all phenomenons of life all can be considered the active track of automatic control information system, and any change of vital movement all can be considered the result that the automatic control information system changes.The appearance of cancer is a kind of unusual biosis, and its root then is that the automatic control information system has occurred unusually.
Forming the section of automatic control information system chain and is made up of some joints, is the ultimate unit of message sense, has the key of saving to link to each other between joint and the joint.As everyone knows, the cell of all malignant tumor all is jejune, and stops at certain stage infinite multiplication on live body of growth, according to the viewpoint of " seeing malignant tumor by life automatic control message sense visual angle ", is to grow certain key of section fracture to have occurred.The automatic control message sense of each cell all possesses the section of growth, has only those just can rupture because of the unsettled internode key of defectiveness suffers enough strikes of sensitive factor, forms incomplete chain.Under the control of this incomplete chain, cell can only be made jejune infinite multiplication, has just occurred cancer clinically.
The present invention uses the characteristic scientific composition of various medicines based on prophylaxis of cancer, and it can improve environment in the cell proliferation, increases the withstand force of cell to carcinogenic factor, prevents the formation of incomplete chain, has avoided the generation of pernicious kind of tumor with this.
The specific embodiment
Take by weighing the powder raw material:
Aspirin 20kg, Sargassum polysaccharides 20kg, vitamin C 30kg, food sterin 30kg, hydrogen meter androsterone 30kg, lycopene 30kg.After above-mentioned each powder raw material stirred, be prepared into powder as required or the piece agent gets final product.Preparation technology of the present invention is a known technology.
Claims (6)
1, cancer prevention oral medicine is characterized in that the medicament (in weight portion) that it comprises the following weight proportion raw material and makes:
Aspirin 10-30
Sargassum polysaccharides 15-45
Vitamin C 25-60
Food sterin 15-45
Hydrogen meter androsterone 20-60
Lycopene 25-50
2, cancer prevention oral medicine according to claim 1 is characterized in that wherein the weight proportion of each raw material is:
Aspirin 10-25
Sargassum polysaccharides 15-40
Vitamin C 25-50
Food sterin 15-40
Hydrogen meter androsterone 20-50
Lycopene 25-40
3, cancer prevention oral medicine according to claim 1 is characterized in that the wherein weight proportion of each raw material:
Aspirin 15-20
Sargassum polysaccharides 20-30
Vitamin C 30-40
Food sterin 20-30
Hydrogen meter androsterone 30-40
Lycopene 30-35
4, cancer prevention oral medicine according to claim 1 is characterized in that the wherein weight proportion of each raw material:
Aspirin 20
Sargassum polysaccharides 20
Vitamin C 30
Food sterin 30
Hydrogen meter androsterone 30
Lycopene 30
5,, it is characterized in that said medicament is a said dosage form on any pharmaceutics according to claim 1,2,3 or 4 described cancer prevention oral medicines.
6, cancer prevention oral medicine according to claim 5 is characterized in that said medicament is powder or piece agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01127482 CN1413590A (en) | 2001-10-26 | 2001-10-26 | Cancer prevention oral medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01127482 CN1413590A (en) | 2001-10-26 | 2001-10-26 | Cancer prevention oral medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1413590A true CN1413590A (en) | 2003-04-30 |
Family
ID=4667433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01127482 Pending CN1413590A (en) | 2001-10-26 | 2001-10-26 | Cancer prevention oral medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1413590A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044407B2 (en) | 2006-04-03 | 2015-06-02 | Health Ever Bio-Tech Co., Ltd. | Multi-carotenoids compositions and uses therefor |
-
2001
- 2001-10-26 CN CN 01127482 patent/CN1413590A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044407B2 (en) | 2006-04-03 | 2015-06-02 | Health Ever Bio-Tech Co., Ltd. | Multi-carotenoids compositions and uses therefor |
| US10022414B2 (en) | 2006-04-03 | 2018-07-17 | Health Ever Bio-Tech Co., Ltd. | Multi-carotenoids compositions and methods |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Islam et al. | A multi-target therapeutic potential of Prunus domestica gum stabilized nanoparticles exhibited prospective anticancer, antibacterial, urease-inhibition, anti-inflammatory and analgesic properties. | |
| Etman et al. | Fucoidan, a natural biopolymer in cancer combating: From edible algae to nanocarrier tailoring | |
| EP0469079B1 (en) | Non-absorbable cholesterol esterase inhibitors for decreasing cholesterol absorption | |
| CN102911281B (en) | Process methods for fucoidan purification from seaweed extracts | |
| US6645948B2 (en) | Nutritional composition for the treatment of connective tissue | |
| EP2679584B1 (en) | Clathrate complex of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene | |
| SG183379A1 (en) | An intra-articular supplementation method for treating joint diseases and injuries | |
| HRP20120228T1 (en) | Cladribine regimen for treating multiple sclerosis | |
| NZ500978A (en) | Use of zinc hyaluronate complex against peptic ulcer | |
| CN1413590A (en) | Cancer prevention oral medicine | |
| JP2011037849A (en) | Hyaluronic acid mixture used for treating and preventing peptic ulcer and duodenal ulcer | |
| WO2006072171A1 (en) | Method for blood glucose control in a mammal by n-acylated glucosamines | |
| EP1512404B1 (en) | External preparations for treating dermatitis | |
| CN1116044C (en) | Antisticking particle and powder containing sodium hyaluronate and their preparation process | |
| WO2003002125B1 (en) | Combination of aminosugars and cysteine or cysteine derivatives | |
| Jaffer et al. | Efficacy and safety of chitosan HEP-40™ in the management of hypercholesterolemia: a randomized, multicenter, placebo-controlled trial | |
| CN103006700A (en) | PH buffering bioactive glass, and preparation method and application thereof | |
| CN103655593B (en) | Composite medicine preparation for prevention and treatment of bacterium and virus polyinfection diseases of livestock as well as preparation method and application thereof | |
| AU3438500A (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
| Hajimohammadebrahim-Ketabforoush et al. | Effect of vitamin D supplementation on postcraniotomy pain after brain tumor surgery: a randomized clinical trial | |
| WO1999043714A1 (en) | Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient | |
| Rewari et al. | Fentanyl pretreatment for alleviation of perineal symptoms following preoperative administration of intravenous dexamethasone sodium phosphate—a prospective, randomized, double blind, placebo controlled study | |
| JPS63156726A (en) | Remedy for bone disease | |
| EP0496233A1 (en) | Pharmaceutical compositions for oral use containing low molecular weight heparin, their preparation and use | |
| CN110893174A (en) | Preparation method of diclofenac sodium enteric-coated tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |